Drugs that contain Etelcalcetide
1. Drug name - PARSABIV
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9278995 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US8377880 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US9701712 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US8999932 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Feb, 2031
(8 years from now) | |
| CN102711789A | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| CN102711789B | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Level |
Jul, 2030
(7 years from now) | |
| IN350519B | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| IN201201196P1 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP3192520B1 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP3539555A1 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP3539555B1 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP3192520A1 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP2459208A4 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP2459208B1 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| EP2459208A2 | KAI PHARMS INC | Therapeutic Agents For Reducing Parathyroid Hormone Levels |
Jul, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11162500 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| US9820938 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| US10344765 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION;INTRAVENOUS | Prescription |
| 5MG/ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 10MG/2ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.